Skip to content

Dolutegravir: update on infant neural tube defects from Botswana

Rebecca Zash at AIDS 2018. Photo by Liz Highleyman.

Efavirenz does not increase the risk of suicidal thoughts or depression in Ugandan adults

Rilpivirine better tolerated, less toxic and more durable than efavirenz in first-line ART

TAF only superior to TDF when used with a boosting agent

Viral suppression protects against long-term liver damage caused by older HIV drugs

Impact of side-effects on retention in HIV care is underestimated, African study suggests

Lipids improved by switching from ritonavir to cobicistat as a booster for darunavir

Case reports of severe dolutegravir-related depression

Taking dolutegravir in the morning may avert insomnia